BioLineRx is trading 6.18% up at $2.80, with no clearly dated company-specific announcement identified on August 18, 2026, to explain the advance.
- The latest identifiable item is a July 8 preclinical GLIX1 combination-data report, updated August 18.
- It does not establish a fresh catalyst for this session.
- Broader markets are lower, so market direction does not explain the move.